by Peter Ciszewski | Jun 18, 2021
Nasha Fitter, Vice President of Rare Disease at Ciitizen, discusses the collaboration between Ciitizen and RARE-X which will improve patient outcomes for rare diseases. Ciitizen is a healthcare technology company that helps patients get full control of their...
by Peter Ciszewski | Jun 17, 2021
Arnold Gammaitoni, PharmD, Vice President of Medical and Scientific Affair at Zogenix, discusses results from a phase 3 clinical trial demonstrating improvements in executive functioning in patients with Lennox-Gastaut syndrome treated with fenfluramine. This...
by Peter Ciszewski | Jun 16, 2021
William D. Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the multidisciplinary approach to treating patients with tenosynovial giant cell tumors (TGCT). TGCT are a group of rare, benign tumors that...
by Peter Ciszewski | Jun 14, 2021
Peter Langmuir, MD, Group Vice President, Oncology Targeted Therapeutics at Incyte, discusses interim data of a phase 2 study assessing the combination of ruxolitinib and parsaclisib in patients with myelofibrosis. Myelofibrosis is a rare cancer characterized...
by Peter Ciszewski | Jun 10, 2021
Mounzer Agha, MD, Director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center and Clinical Director of the Hematopoietic Stem Cell Transplantation of UPMC, discusses data of Cohort A of the CARTITUDE-2 study. This study is evaluating...
